This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The two adjuvant therapies under examination were switching to exemestane after 2 or 3 years of tamoxifen therapy versus continuing on tamoxifen for 5 years. These therapies were administered to postmenopausal women with earlystage BC. Both hormone receptor (HR)-positive and HR-unknown women were considered.
Location/setting
USA. Secondary care/hospital.
Methods

Analytical approach:
This economic evaluation was based on a Markov model that was developed to predict the long-term clinical and economic impact of the two strategies. The time horizon of the analysis was 35 years (patients' lifetime since women were assumed to have an average age of 64 years at model entry). The perspective adopted in the study was not explicitly stated.
Effectiveness data:
The clinical estimates used to populate the decision model were identified through a selection of recent and relevant studies. However, the authors did not report details of a review of the literature. Disease-and treatment-related events (mainly osteoporosis for exemestane) were derived from the exemestane pivotal trial (Intergroup Exemestane Study, IES), which followed patients for a maximum of 48 months. A second key source of data was the Surveillance Epidemiology and End Results (SEER) database, covering 12 calendar years from 1991 to 2002, which was used to estimate survival for patients with different stages of cancer. The Kaplan-Meier approach was used to extrapolate clinical data to a long-term horizon. A number of simplifying assumptions were also made.
Monetary benefit and utility valuations:
The utility estimates were based on multiple sources, including nationally representative values for the US population and published studies. The summary benefit measures were the life-years (LYs), disease-free months (DFM) and quality-adjusted life-years (QALYs). These were estimated by combing survival data derived from the model and utility valuations. All benefit measures were discounted at an annual rate of 3%, but undiscounted values were also presented.
Measure of benefit:
Cost data:
The categories of costs included in the analysis were drugs, dual x-ray absorptiometry bone density scans (only for exemestane patients), treatment of local and distant recurrences, and treatment of endometrial cancer and osteoporosis. The drug costs were estimated from the lowest published US average wholesale prices. The costs and resource use associated with cancer recurrence treatment were based on the SEER-Medicare registry. The costs of managing endometrial cancer and osteoporosis were derived from published studies. The price year was 2004 and the costs were in US dollars ($). Given the long timeframe of the analysis, an annual discount rate of 3% was applied.
Analysis of uncertainty:
The issue of uncertainty was addressed by means of probabilistic and deterministic sensitivity analyses. In the former (probabilistic), a non-parametric bootstrapping of patient populations in the IES and SEER-Medicare databases was undertaken in order to generate confidence intervals (CIs) and cost-effectiveness acceptability curves. In the latter (deterministic), plausible ranges of values were considered for key model inputs (base-case value +/-two standard errors or base-case value +/-25%) in a univariate analysis. In an alternative analysis, data on treatment effects on BC were derived from published sources rather than by extrapolation from the IES database.
Results
The switch to exemestane led to 0.22 additional discounted QALYs (8.77 versus 8.99) and $4,400 additional lifetime costs ($7,724 versus $12,124) .
The incremental cost per DFM with exemestane was $680, the incremental cost per LY gained was $13,300, and the incremental cost per QALY gained was $20,100 (95% CI: 12,100 to 59,000).
In patients with HR-positive BC (thus, excluding HR-unknown women), the incremental cost per QALY was even more favourable ($16,600 per QALY).
The cost-effectiveness acceptability curve generated in the probabilistic sensitivity analysis showed that the probability that exemestane is cost-effective was 70.5% at a threshold of $25,000 per QALY and 96.4% at a threshold of $50,000 per QALY. The deterministic sensitivity analysis showed that the model results were most sensitive to variations in exemestane hazard ratio for distant recurrence, patient utility in the no recurrence state, and the daily cost of exemestane. However, in one of the cases analysed, the incremental cost per QALY for the switching strategy turned out to be higher than $50,000. The use of alternative data for treatment effectiveness improved or worsen the incremental cost-utility results, depending on whether favourable or unfavourable rates for exemestane were used. However, in general, the costeffectiveness of exemestane remained favourable.
